Best response by 6 months
| Modified Cheson response criteria7 . | Total, n (%) . | 95% CI . | |
|---|---|---|---|
| CR | Blasts 0%, WBC >4 × 109/L, hemoglobin ≥ 10 g/L, platelets 100 × 109/L | 0 (0) | — |
| CR-i | Blasts 0% incomplete count recovery | 2 (8.1) | 0.1-26.0 |
| PR | ≥50% decrease in peripheral blood blasts, regardless of blood counts | 9 (36.0) | 18.0-57.5 |
| NR | Not meeting any of the above criteria | 7 (28.0) | 12.1-49.4 |
| NR (secondary to unevaluable) | Adverse event (n = 4)*; refused further treatment (n = 1); lack of baseline blasts (n = 2) | 7 (28.0) | 12.1-49.4 |
| Modified Cheson response criteria7 . | Total, n (%) . | 95% CI . | |
|---|---|---|---|
| CR | Blasts 0%, WBC >4 × 109/L, hemoglobin ≥ 10 g/L, platelets 100 × 109/L | 0 (0) | — |
| CR-i | Blasts 0% incomplete count recovery | 2 (8.1) | 0.1-26.0 |
| PR | ≥50% decrease in peripheral blood blasts, regardless of blood counts | 9 (36.0) | 18.0-57.5 |
| NR | Not meeting any of the above criteria | 7 (28.0) | 12.1-49.4 |
| NR (secondary to unevaluable) | Adverse event (n = 4)*; refused further treatment (n = 1); lack of baseline blasts (n = 2) | 7 (28.0) | 12.1-49.4 |
Grade 5 pneumonia (n = 1), grade 3 neutropenic fever, muscle weakness and fatigue (n = 1), grade 4 febrile neutropenia and sepsis (n = 1), and grade 3 febrile neutropenia (n = 1).